Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CYT001
- Development stage
- Unknown
- Lead developer
- CYTLIMIC
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Administration
- Intradermal
01
Overview
**CYT001** is an investigational, AI-designed therapeutic peptide cancer vaccine developed for hepatocellular carcinoma. It contains shared tumor-antigen peptides derived from heat shock protein 70 and glypican-3, together with the immunostimulatory adjuvants poly-ICLC and eftilagimod alpha. The peptide antigens are intended to elicit antigen-specific cytotoxic T-cell responses against tumor cells expressing the corresponding antigens, while poly-ICLC and eftilagimod alpha stimulate innate and antigen-presenting-cell activity to strengthen antitumor immunity and convert immunologically cold tumors into inflamed tumors. CYT001 was evaluated in the Phase I CRESCENT 1 study in patients with unresectable advanced hepatocellular carcinoma. ([nec.com](https://www.nec.com/en/press/201908/global_20190809_01.html))
02
Targets
GPC3 (Glypican-3)Heat shock protein 70-derived peptide epitopeMHC II (Major histocompatibility complex class II receptor)IFIH1 (MDA5)TLR3 (Toll-like receptor 3)HSPA1A (HSP70-1A)
Beyond the preview
Go deeper on CYT001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CYT001.